cf-301
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started May 1, 2015 (NCT02439359)
Timeline
Indications
Studied for
Mechanism of action
- BiofilmHYDROLYTIC ENZYME
Biofilm hydrolytic enzyme
Bacteriophage-derived antistaphylococcal lysin
- PeptidoglycanHYDROLYTIC ENZYME
Peptidoglycan hydrolytic enzyme
Bacteriophage-derived antistaphylococcal lysin
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297925 ↗
Also known as
- cf-301
- cf-301
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04160468 | Phase 3 | Dec 31, 2019 | ContraFect |
| NCT03163446 | Phase 2 | May 23, 2017 | ContraFect |
| NCT02439359 | Phase 1 | May 1, 2015 | ContraFect |
| NCT04597242 | N/A | — | ContraFect |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ContraFect | For profit | 4 | 4 | 4 | 2015 |
1 organizations
Page 1 / 1